BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Baber U, Mehran R, Giustino G, Cohen DJ, Henry TD, Sartori S, Ariti C, Litherland C, Dangas G, Gibson CM, Krucoff MW, Moliterno DJ, Kirtane AJ, Stone GW, Colombo A, Chieffo A, Kini AS, Witzenbichler B, Weisz G, Steg PG, Pocock S. Coronary Thrombosis and Major Bleeding After PCI With Drug-Eluting Stents: Risk Scores From PARIS. J Am Coll Cardiol 2016;67:2224-34. [PMID: 27079334 DOI: 10.1016/j.jacc.2016.02.064] [Cited by in Crossref: 286] [Cited by in F6Publishing: 171] [Article Influence: 57.2] [Reference Citation Analysis]
Number Citing Articles
1 Misumida N, Ogunbayo GO, Kim SM, Olorunfemi O, Elbadawi A, Charnigo RJ, Abdel-Latif A, Ziada KM. Higher Risk of Bleeding in Asians Presenting With ST-Segment Elevation Myocardial Infarction: Analysis of the National Inpatient Sample Database. Angiology 2018;69:548-54. [PMID: 28905638 DOI: 10.1177/0003319717730168] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 2.8] [Reference Citation Analysis]
2 Natsuaki M, Morimoto T, Yamaji K, Watanabe H, Yoshikawa Y, Shiomi H, Nakagawa Y, Furukawa Y, Kadota K, Ando K, Akasaka T, Hanaoka KI, Kozuma K, Tanabe K, Morino Y, Muramatsu T, Kimura T; CREDO‐Kyoto PCI/CABG Registry Cohort 2, RESET, and NEXT trial investigators. Prediction of Thrombotic and Bleeding Events After Percutaneous Coronary Intervention: CREDO-Kyoto Thrombotic and Bleeding Risk Scores. J Am Heart Assoc 2018;7:e008708. [PMID: 29789335 DOI: 10.1161/JAHA.118.008708] [Cited by in Crossref: 55] [Cited by in F6Publishing: 8] [Article Influence: 18.3] [Reference Citation Analysis]
3 Verdoia M, Kedhi E, Suryapranata H, Frati G, Biondi-Zoccai G, De Luca G. Benefits of short-term or prolonged as compared to standard 1 year DAPT in patients with acute coronary syndrome treated with drug-eluting stents: a meta-analysis of 9 randomized trials. J Thromb Thrombolysis 2020;50:337-54. [PMID: 31919736 DOI: 10.1007/s11239-019-02033-2] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
4 Swan D, Loughran N, Makris M, Thachil J. Management of bleeding and procedures in patients on antiplatelet therapy. Blood Reviews 2020;39:100619. [DOI: 10.1016/j.blre.2019.100619] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]
5 Ishihara T, Sotomi Y, Tsujimura T, Iida O, Kobayashi T, Hamanaka Y, Omatsu T, Sakata Y, Higuchi Y, Mano T. Impact of diabetes mellitus on the early-phase arterial healing after drug-eluting stent implantation. Cardiovasc Diabetol 2020;19:203. [PMID: 33267863 DOI: 10.1186/s12933-020-01173-7] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
6 Li Y, Jing Q, Wang B, Wang X, Li J, Qiao S, Chen S, Angiolillo DJ, Han Y. Extended antiplatelet therapy with clopidogrel alone versus clopidogrel plus aspirin after completion of 9- to 12-month dual antiplatelet therapy for acute coronary syndrome patients with both high bleeding and ischemic risk. Rationale and design of the OPT-BIRISK double-blinded, placebo-controlled randomized trial. Am Heart J 2020;228:1-7. [PMID: 32739652 DOI: 10.1016/j.ahj.2020.07.005] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
7 Cao D, Dangas G, Mehran R. Long-Term Ticagrelor in Stable Patients With Prior Myocardial Infarction: Bleeding Avoidance First and Foremost. J Am Heart Assoc 2021;10:e019889. [PMID: 33559475 DOI: 10.1161/JAHA.120.019889] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
8 Lattuca B, Cayla G, Silvain J, Cuisset T, Leclercq F, Manzo-Silberman S, Saint-Etienne C, Delarche N, El Mahmoud R, Carrié D, Souteyrand G, Kerneis M, Hauguel-Moreau M, Zeitouni M, Guedeney P, Diallo A, Collet JP, Vicaut E, Montalescot G; ACTION Study Group. Bleeding in the Elderly: Risk Factors and Impact on Clinical Outcomes After an Acute Coronary Syndrome, a Sub-study of the Randomized ANTARCTIC Trial. Am J Cardiovasc Drugs 2021. [PMID: 34191259 DOI: 10.1007/s40256-021-00468-8] [Reference Citation Analysis]
9 Ferrante G, Condorelli G, Pagnotta P, Reimers B. Dual Antiplatelet Therapy Continuation Beyond 1 Year After Drug-Eluting Stents: A Meta-Analysis of Randomized Trials. Circ: Cardiovascular Interventions 2017;10. [DOI: 10.1161/circinterventions.116.004139] [Cited by in Crossref: 4] [Article Influence: 1.0] [Reference Citation Analysis]
10 Gao C, Tomaniak M, Takahashi K, Kawashima H, Wang R, Hara H, Ono M, Montalescot G, Garg S, Haude M, Slagboom T, Vranckx P, Valgimigli M, Windecker S, van Geuns RJ, Hamm C, Steg PG, Onuma Y, Angiolillo DJ, Serruys PW. Ticagrelor monotherapy in patients with concomitant diabetes mellitus and chronic kidney disease: a post hoc analysis of the GLOBAL LEADERS trial. Cardiovasc Diabetol 2020;19:179. [PMID: 33066794 DOI: 10.1186/s12933-020-01153-x] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
11 Marquis-Gravel G, Roe MT, Harrington RA, Muñoz D, Hernandez AF, Jones WS. Revisiting the Role of Aspirin for the Primary Prevention of Cardiovascular Disease. Circulation 2019;140:1115-24. [PMID: 31545683 DOI: 10.1161/CIRCULATIONAHA.119.040205] [Cited by in Crossref: 13] [Cited by in F6Publishing: 9] [Article Influence: 6.5] [Reference Citation Analysis]
12 Baber U, Dangas G, Cohen DJ, Gibson CM, Mehta SR, Angiolillo DJ, Pocock SJ, Krucoff MW, Kastrati A, Ohman EM, Steg PG, Badimon J, Zafar MU, Chandrasekhar J, Sartori S, Aquino M, Mehran R. Ticagrelor with aspirin or alone in high-risk patients after coronary intervention: Rationale and design of the TWILIGHT study. American Heart Journal 2016;182:125-34. [DOI: 10.1016/j.ahj.2016.09.006] [Cited by in Crossref: 87] [Cited by in F6Publishing: 59] [Article Influence: 17.4] [Reference Citation Analysis]
13 Chandiramani R, Cao D, Claessen BE, Sorrentino S, Guedeney P, Blum M, Goel R, Roumeliotis A, Krucoff M, Kozuma K, Ge J, Seth A, Makkar R, Bangalore S, Bhatt DL, Angiolillo DJ, Ruster K, Wang J, Saito S, Neumann FJ, Hermiller J, Valgimigli M, Mehran R. Sex-Related Differences in Patients at High Bleeding Risk Undergoing Percutaneous Coronary Intervention: A Patient-Level Pooled Analysis From 4 Postapproval Studies. J Am Heart Assoc 2020;9:e014611. [PMID: 32223396 DOI: 10.1161/JAHA.119.014611] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 4.0] [Reference Citation Analysis]
14 Du R, Wang Y, Huang Y, Zhao Y, Zhang D, Du D, Zhang Y, Li Z, Mcginty S, Pontrelli G, Yin T, Wang G. Design and testing of hydrophobic core/hydrophilic shell nano/micro particles for drug-eluting stent coating. NPG Asia Mater 2018;10:642-58. [DOI: 10.1038/s41427-018-0064-z] [Cited by in Crossref: 22] [Cited by in F6Publishing: 7] [Article Influence: 7.3] [Reference Citation Analysis]
15 Barillà F, Pelliccia F, Borzi M, Camici P, Cas LD, Di Biase M, Indolfi C, Mercuro G, Montemurro V, Padeletti L, Filardi PP, Vizza CD, Romeo F; 2015–2016 Board of the Italian Society of Cardiology. Optimal duration of dual anti-platelet therapy after percutaneous coronary intervention: 2016 consensus position of the Italian Society of Cardiology. J Cardiovasc Med (Hagerstown) 2017;18:1-9. [PMID: 27635937 DOI: 10.2459/JCM.0000000000000434] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
16 Chen Y, Cao J, Peng W, Chen W. Neurotrophin-3 accelerates reendothelialization through inducing EPC mobilization and homing. Open Life Sci 2020;15:241-50. [PMID: 33817212 DOI: 10.1515/biol-2020-0028] [Reference Citation Analysis]
17 Song L, Guan C, Yan H, Qiao S, Wu Y, Yuan J, Dou K, Yang Y, Dangas GD, Xu B. Validation of contemporary risk scores in predicting coronary thrombotic events and major bleeding in patients with acute coronary syndrome after drug-eluting stent implantations. Catheter Cardiovasc Interv 2018;91:573-81. [DOI: 10.1002/ccd.27468] [Cited by in Crossref: 14] [Cited by in F6Publishing: 5] [Article Influence: 4.7] [Reference Citation Analysis]
18 Yoshioka N, Takagi K, Morita Y, Kanzaki Y, Nagai H, Watanabe N, Morishima I. Bleeding events and mid-term mortality in the patients undergoing endovascular interventions for peripheral artery disease of the lower limbs based on the academic research consortium high bleeding risk criteria. Heart Vessels 2021;36:1336-49. [PMID: 33616719 DOI: 10.1007/s00380-021-01804-3] [Reference Citation Analysis]
19 Urban P, Mehran R, Colleran R, Angiolillo DJ, Byrne RA, Capodanno D, Cuisset T, Cutlip D, Eerdmans P, Eikelboom J, Farb A, Gibson CM, Gregson J, Haude M, James SK, Kim HS, Kimura T, Konishi A, Laschinger J, Leon MB, Magee PFA, Mitsutake Y, Mylotte D, Pocock S, Price MJ, Rao SV, Spitzer E, Stockbridge N, Valgimigli M, Varenne O, Windhoevel U, Yeh RW, Krucoff MW, Morice MC. Defining high bleeding risk in patients undergoing percutaneous coronary intervention: a consensus document from the Academic Research Consortium for High Bleeding Risk. Eur Heart J 2019;40:2632-53. [PMID: 31116395 DOI: 10.1093/eurheartj/ehz372] [Cited by in Crossref: 128] [Cited by in F6Publishing: 75] [Article Influence: 128.0] [Reference Citation Analysis]
20 Shima Y, Miura K, Shimada T, Ohya M, Murai R, Kubo S, Tada T, Tanaka H, Fuku Y, Kadota K. Impact of ischemic risk factors on long-term outcomes in patients with and without high bleeding risk. Int J Cardiol 2021;326:12-8. [PMID: 33152414 DOI: 10.1016/j.ijcard.2020.10.073] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
21 Lee SY, Hong MK, Shin DH, Kim JS, Kim BK, Ko YG, Choi D, Jang Y, Kim HS, Valgimigli M, Colombo A, Gilard M, Palmerini T, Stone GW. Association Between Duration of Dual Antiplatelet Therapy and Angiographic Multivessel Disease on Outcomes in Patients Treated With Newer-Generation Drug-Eluting Stents. Circ Cardiovasc Interv 2016;9:e004256. [PMID: 27803041 DOI: 10.1161/CIRCINTERVENTIONS.116.004256] [Cited by in Crossref: 6] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
22 Berger JS. Oral Antiplatelet Therapy for Secondary Prevention of Acute Coronary Syndrome. Am J Cardiovasc Drugs 2018;18:457-72. [PMID: 29987548 DOI: 10.1007/s40256-018-0291-2] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
23 Chichareon P, Modolo R, Kerkmeijer L, Tomaniak M, Kogame N, Takahashi K, Chang CC, Komiyama H, Moccetti T, Talwar S, Colombo A, Maillard L, Barlis P, Wykrzykowska J, Piek JJ, Garg S, Hamm C, Steg PG, Jüni P, Valgimigli M, Windecker S, Onuma Y, Mehran R, Serruys PW. Association of Sex With Outcomes in Patients Undergoing Percutaneous Coronary Intervention: A Subgroup Analysis of the GLOBAL LEADERS Randomized Clinical Trial. JAMA Cardiol 2020;5:21-9. [PMID: 31693078 DOI: 10.1001/jamacardio.2019.4296] [Cited by in Crossref: 14] [Cited by in F6Publishing: 6] [Article Influence: 14.0] [Reference Citation Analysis]
24 Urban P, Gregson J, Owen R, Mehran R, Windecker S, Valgimigli M, Varenne O, Krucoff M, Saito S, Baber U, Chevalier B, Capodanno D, Morice MC, Pocock S. Assessing the Risks of Bleeding vs Thrombotic Events in Patients at High Bleeding Risk After Coronary Stent Implantation: The ARC-High Bleeding Risk Trade-off Model. JAMA Cardiol 2021;6:410-9. [PMID: 33404627 DOI: 10.1001/jamacardio.2020.6814] [Cited by in Crossref: 7] [Cited by in F6Publishing: 3] [Article Influence: 7.0] [Reference Citation Analysis]
25 Giustino G, Harari R, Baber U, Sartori S, Stone GW, Leon MB, Windecker S, Serruys PW, Kastrati A, Von Birgelen C, Kimura T, Stefanini GG, Dangas GD, Wijns W, Steg PG, Morice MC, Camenzind E, Weisz G, Smits PC, Sorrentino S, Sharma M, Farhan S, Faggioni M, Kandzari D, Galatius S, Jeger RV, Valgimigli M, Itchhaporia D, Mehta L, Kim HS, Chieffo A, Mehran R. Long-term Safety and Efficacy of New-Generation Drug-Eluting Stents in Women With Acute Myocardial Infarction: From the Women in Innovation and Drug-Eluting Stents (WIN-DES) Collaboration. JAMA Cardiol 2017;2:855-62. [PMID: 28658478 DOI: 10.1001/jamacardio.2017.1978] [Cited by in Crossref: 20] [Cited by in F6Publishing: 13] [Article Influence: 10.0] [Reference Citation Analysis]
26 Templin C, Di Vece D. Risk scores in predicting adverse events following acute coronary syndrome. Lancet 2021;397:172-3. [PMID: 33453766 DOI: 10.1016/S0140-6736(21)00038-6] [Reference Citation Analysis]
27 Urban P, Mehran R, Colleran R, Angiolillo DJ, Byrne RA, Capodanno D, Cuisset T, Cutlip D, Eerdmans P, Eikelboom J, Farb A, Gibson CM, Gregson J, Haude M, James SK, Kim HS, Kimura T, Konishi A, Laschinger J, Leon MB, Magee PFA, Mitsutake Y, Mylotte D, Pocock S, Price MJ, Rao SV, Spitzer E, Stockbridge N, Valgimigli M, Varenne O, Windhoevel U, Yeh RW, Krucoff MW, Morice MC. Defining High Bleeding Risk in Patients Undergoing Percutaneous Coronary Intervention. Circulation 2019;140:240-61. [PMID: 31116032 DOI: 10.1161/CIRCULATIONAHA.119.040167] [Cited by in Crossref: 162] [Cited by in F6Publishing: 31] [Article Influence: 81.0] [Reference Citation Analysis]
28 Ishida M, Takahashi F, Goto I, Niiyama M, Saitoh H, Sakamoto T, Maegawa Y, Osaki T, Nishiyama O, Endo H, Sakamoto R, Kojima T, Koeda Y, Kimura T, Itoh T, Morino Y; REIWA investigators. Clinical outcomes of patients treated using very short duration dual antiplatelet therapy after implantation of biodegradable-polymer drug-eluting stents: rationale and design of a prospective multicenter REIWA registry. Cardiovasc Interv Ther 2020;35:398-404. [PMID: 32776221 DOI: 10.1007/s12928-020-00694-y] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
29 Thomas MR, Lip GY. Novel Risk Markers and Risk Assessments for Cardiovascular Disease. Circ Res 2017;120:133-49. [PMID: 28057790 DOI: 10.1161/CIRCRESAHA.116.309955] [Cited by in Crossref: 71] [Cited by in F6Publishing: 34] [Article Influence: 17.8] [Reference Citation Analysis]
30 Esmonde S, Sharma D, Peace A. Antiplatelet agents in uncertain clinical scenarios-a bleeding nightmare. Cardiovasc Diagn Ther 2018;8:647-62. [PMID: 30498688 DOI: 10.21037/cdt.2018.06.09] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
31 Cho SW, Franchi F, Angiolillo DJ. Role of oral anticoagulant therapy for secondary prevention in patients with stable atherothrombotic disease manifestations. Ther Adv Hematol 2019;10:2040620719861475. [PMID: 31321012 DOI: 10.1177/2040620719861475] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
32 Angiolillo DJ, Goodman SG, Bhatt DL, Eikelboom JW, Price MJ, Moliterno DJ, Cannon CP, Tanguay JF, Granger CB, Mauri L, Holmes DR, Gibson CM, Faxon DP. Antithrombotic Therapy in Patients With Atrial Fibrillation Undergoing Percutaneous Coronary Intervention: A North American Perspective-2016 Update. Circ Cardiovasc Interv 2016;9:e004395. [PMID: 27803042 DOI: 10.1161/CIRCINTERVENTIONS.116.004395] [Cited by in Crossref: 68] [Cited by in F6Publishing: 11] [Article Influence: 17.0] [Reference Citation Analysis]
33 Fujisaki T, Kuno T, Ando T, Briasoulis A, Takagi H, Bangalore S. Potent P2Y12 inhibitors versus Clopidogrel in elderly patients with acute coronary syndrome: Systematic review and meta-analysis. Am Heart J 2021;237:34-44. [PMID: 33737060 DOI: 10.1016/j.ahj.2021.03.009] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
34 Cordero A, García-acuña JM, Rodríguez-mañero M, Agra-bermejo R, Cid B, Alvarez B, Bertomeu-gonzález V, Fácila L, Bertomeu-martínez V, González-juanatey JR. Prevalence, long-term prognosis and medical alternatives for patients admitted for acute coronary syndromes and prasugrel contraindication. International Journal of Cardiology 2018;270:36-41. [DOI: 10.1016/j.ijcard.2018.06.057] [Cited by in Crossref: 8] [Cited by in F6Publishing: 3] [Article Influence: 2.7] [Reference Citation Analysis]
35 Capodanno D, Alberts M, Angiolillo DJ. Antithrombotic therapy for secondary prevention of atherothrombotic events in cerebrovascular disease. Nat Rev Cardiol 2016;13:609-22. [PMID: 27489191 DOI: 10.1038/nrcardio.2016.111] [Cited by in Crossref: 15] [Cited by in F6Publishing: 13] [Article Influence: 3.0] [Reference Citation Analysis]
36 Garot P, Morice M, Tresukosol D, Pocock SJ, Meredith IT, Abizaid A, Carrié D, Naber C, Iñiguez A, Talwar S, Menown IB, Christiansen EH, Gregson J, Copt S, Hovasse T, Lurz P, Maillard L, Krackhardt F, Ong P, Byrne J, Redwood S, Windhövel U, Greene S, Stoll H, Urban P, Urban P, Morice M, Abizaid A, Meredith IT, Pocock SJ, Carrié D, Naber C, Greene S, Stoll H. 2-Year Outcomes of High Bleeding Risk Patients After Polymer-Free Drug-Coated Stents. Journal of the American College of Cardiology 2017;69:162-71. [DOI: 10.1016/j.jacc.2016.10.009] [Cited by in Crossref: 87] [Cited by in F6Publishing: 50] [Article Influence: 21.8] [Reference Citation Analysis]
37 Li J, Li Y, Qiu M, Li Z, Yang J, Wang X, Bao D, Wang X, Han Y. Impact of dual antiplatelet therapy duration on 1‐year clinical outcomes in diabetic patients with acute coronary syndrome undergoing percutaneous coronary intervention: Insights from the real‐world OPT‐CAD study. Catheter Cardiovasc Interv 2020;95:579-86. [DOI: 10.1002/ccd.28653] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
38 Verdoia M, Suryapranata H, Damen S, Camaro C, Benit E, Barbieri L, Rasoul S, Liew HB, Polad J, Ahmad WAW, Zambahari R, Lalmand J, van der Schaaf RJ, Koh TH, Timmermans P Sr, Dilling-Boer D, Veenstra LF, Van't Hof AWJ, Lee SWL, Roolvink V, Ligtenberg E, Postma S, Kolkman EJJ, Brouwer MA, Kedhi E, De Luca G. Gender differences with short-term vs 12 months dual antiplatelet therapy in patients with acute coronary syndrome treated with the COMBO dual therapy stent: 2-years follow-up results of the REDUCE trial. J Thromb Thrombolysis 2021. [PMID: 33847862 DOI: 10.1007/s11239-021-02439-x] [Reference Citation Analysis]
39 Watanabe H, Domei T, Morimoto T, Natsuaki M, Shiomi H, Toyota T, Ohya M, Suwa S, Takagi K, Nanasato M, Hata Y, Yagi M, Suematsu N, Yokomatsu T, Takamisawa I, Doi M, Noda T, Okayama H, Seino Y, Tada T, Sakamoto H, Hibi K, Abe M, Kawai K, Nakao K, Ando K, Tanabe K, Ikari Y, Hanaoka KI, Morino Y, Kozuma K, Kadota K, Furukawa Y, Nakagawa Y, Kimura T; STOPDAPT-2 Investigators. Effect of 1-Month Dual Antiplatelet Therapy Followed by Clopidogrel vs 12-Month Dual Antiplatelet Therapy on Cardiovascular and Bleeding Events in Patients Receiving PCI: The STOPDAPT-2 Randomized Clinical Trial. JAMA 2019;321:2414-27. [PMID: 31237644 DOI: 10.1001/jama.2019.8145] [Cited by in Crossref: 279] [Cited by in F6Publishing: 180] [Article Influence: 139.5] [Reference Citation Analysis]
40 Dillinger JG, Laine M, Bouajila S, Paganelli F, Henry P, Bonello L. Antithrombotic strategies in elderly patients with acute coronary syndrome. Arch Cardiovasc Dis 2021;114:232-45. [PMID: 33632631 DOI: 10.1016/j.acvd.2020.12.002] [Reference Citation Analysis]
41 Spirito A, Gragnano F, Corpataux N, Vaisnora L, Galea R, Svab S, Gargiulo G, Siontis GCM, Praz F, Lanz J, Billinger M, Hunziker L, Stortecky S, Pilgrim T, Capodanno D, Urban P, Pocock S, Mehran R, Heg D, Windecker S, Räber L, Valgimigli M. Sex-Based Differences in Bleeding Risk After Percutaneous Coronary Intervention and Implications for the Academic Research Consortium High Bleeding Risk Criteria. J Am Heart Assoc 2021;10:e021965. [PMID: 34098740 DOI: 10.1161/JAHA.121.021965] [Reference Citation Analysis]
42 Verheugt FWA, Ten Berg JM, Storey RF, Cuisset T, Granger CB. Antithrombotics: From Aspirin to DOACs in Coronary Artery Disease and Atrial Fibrillation (Part 3/5). J Am Coll Cardiol 2019;74:699-711. [PMID: 31277840 DOI: 10.1016/j.jacc.2019.02.080] [Cited by in Crossref: 9] [Cited by in F6Publishing: 2] [Article Influence: 4.5] [Reference Citation Analysis]
43 Saito Y, Kobayashi Y, Tanabe K, Ikari Y. Antithrombotic therapy after percutaneous coronary intervention from the Japanese perspective. Cardiovasc Interv and Ther 2020;35:19-29. [DOI: 10.1007/s12928-019-00633-6] [Cited by in Crossref: 21] [Cited by in F6Publishing: 9] [Article Influence: 10.5] [Reference Citation Analysis]
44 Silvain J, Lattuca B, Beygui F, Rangé G, Motovska Z, Dillinger J, Boueri Z, Brunel P, Lhermusier T, Pouillot C, Larrieu-ardilouze E, Boccara F, Labeque J, Guedeney P, El Kasty M, Laredo M, Dumaine R, Ducrocq G, Collet J, Cayla G, Blanchart K, Kala P, Vicaut E, Montalescot G, Silvain J, Collet J, Montalescot G, Kerneis M, Braik N, Barthelemy O, Helft G, Lefeuvre C, Choussat R, Hauguel M, Zeitouni M, Cuisset T, Bonnet J, Deharo P, Lattuca B, Cayla G, Cornillet L, Ledermann B, Lonjon C, Schmutz L, Range G, Albert F, Demicheli T, Roussel L, Bensaid R, Thuaire C, Dillinger J, Henry P, Manzo-silberman S, Sideris G, Logeart D, Spagnoli V, Cacoub L, Pouillot C, Vi-fane JR, Glasenapp J, Bougrini K, Combaret N, Motreff P, Souteyrand G, Amonchot A, Mouyen T, Lhermusier T, Carrie D, Bouisset F, Chollet T, Campelo-parada F, Delarche N, Schiele F, Besutti M, Hauguel-moreau M, El Mahmoud R, Caussin C, Zoheir M, Veugeois A, Dibie A, Varenne O, Picard F, Lafont A, Adjedj J, Degrell P, Beygui F, Sabatier R, Roule V, Bignon M, Blanchart K, Ardouin P, Lemaitre A, Briet C, Boueri Z, Goube P, Coste P, Cetran L, Clerc J, Le Breton H, Boulmier D, Auffret V, Labeque J, Bonas J, Georges J, Livarek B, Blicq E, Baron N, Gibault-genty G, Cottin Y, Lhuillier I, Richard C, Lorgis L, Buffet P, Spaulding C, Karam N, Puymirat E, Mennuni M, Poulidakis E, Bonnevie L, Boccara F, Chauvet M, Dufour L, Ancedy Y, Ederhy S, Etienney A, Bellemain-appaix A, Bitton N, Jacq L, Saint-etienne C, Leclercq F, Roubille F, Rioufol G, Derimay F, Goralski M, Yafi W, Filippi E, Kermarrec A, Le Ray C, Merlet A, Loirat A, Brunel P, Brunet D, Ravisy J, Mock L, Molins G, Carre M, Bressollette E, Christiaens L, Larrieu-ardilouze E, Cador RC, Van Belle E, Lemesle G, Delhaye C, Vincent F, Porouchani S, Spillemaeker H, Petit K, Ressencourt O, Carre M, Humeau V, Jourda F, Arnould M, Chassaing S, Isaaz K, Payot L, Montsegu J, Faurie B, Pansieri M, Metge M, Moussa K, Pankert M, Morel O, Hess S, Maillard L, Manigold T, Letocart V, Plessis J, Berthome P, Bonin M, Huchet F, Teiger E, Gallet R, Mouillet G, Boukantar M, El Mahmoud R, Nejjari M, Attias D, Cacoub L, Steinecker M, Huchet F, Motovska Z, Kozel M, Stelmach Z, Hlinomaz O, Rezek M, Novak M, Sitar J, Semenka J, Kala P, Bocek O, Štipal R, Poloczek M, Kanovský J, Jerabek P, Karasek J, Hruskova S, Branny M, Mrozek J, Grezl T, Pleva L, Kukla P, Porzer M. Ticagrelor versus clopidogrel in elective percutaneous coronary intervention (ALPHEUS): a randomised, open-label, phase 3b trial. The Lancet 2020;396:1737-44. [DOI: 10.1016/s0140-6736(20)32236-4] [Cited by in Crossref: 12] [Cited by in F6Publishing: 3] [Article Influence: 12.0] [Reference Citation Analysis]
45 Goel R, Cao D, Chandiramani R, Roumeliotis A, Blum M, Bhatt DL, Angiolillo DJ, Ge J, Seth A, Saito S, Krucoff M, Kozuma K, Makkar RM, Bangalore S, Wang L, Koo K, Neumann F, Hermiller J, Stefanini G, Valgimigli M, Mehran R. Comparative influence of bleeding and ischemic risk factors on diabetic patients undergoing percutaneous coronary intervention with everolimus‐eluting stents. Catheter Cardiovasc Interv. [DOI: 10.1002/ccd.29314] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
46 Buccheri S, Angiolillo DJ, Capodanno D. Evolving paradigms in antithrombotic therapy for anticoagulated patients undergoing coronary stenting. Ther Adv Cardiovasc Dis 2019;13:1753944719891688. [PMID: 31814532 DOI: 10.1177/1753944719891688] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
47 Giustino G, Chieffo A, Palmerini T, Valgimigli M, Feres F, Abizaid A, Costa RA, Hong M, Kim B, Jang Y, Kim H, Park KW, Gilard M, Morice M, Sawaya F, Sardella G, Genereux P, Redfors B, Leon MB, Bhatt DL, Stone GW, Colombo A. Efficacy and Safety of Dual Antiplatelet Therapy After Complex PCI. Journal of the American College of Cardiology 2016;68:1851-64. [DOI: 10.1016/j.jacc.2016.07.760] [Cited by in Crossref: 198] [Cited by in F6Publishing: 113] [Article Influence: 39.6] [Reference Citation Analysis]
48 Nakamura M, Iijima R. Implications and characteristics of high bleeding risk in East Asian patients undergoing percutaneous coronary intervention: Start with what is right rather than what is acceptable. J Cardiol 2021;78:91-8. [PMID: 33358236 DOI: 10.1016/j.jjcc.2020.12.004] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
49 Verdoia M, Khedi E, Suryapranata H, De Luca G. Very short dual antiplatelet therapy after PCI and new DES: a meta-analysis of 5 randomized trials. Rev Esp Cardiol (Engl Ed) 2021;74:140-8. [PMID: 32482558 DOI: 10.1016/j.rec.2020.03.009] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
50 Redfors B, Ben-yehuda O, Lin S, Furer A, Kirtane AJ, Witzenbichler B, Weisz G, Stuckey TD, Maehara A, Généreux P, Giustino G, Rinaldi MJ, Neumann F, Metzger DC, Henry TD, Cox DA, Duffy PL, Mazzaferri EL, Ayele GM, Mehran R, Mintz GS, Stone GW. Quantifying Ischemic Risk After Percutaneous Coronary Intervention Attributable to High Platelet Reactivity on Clopidogrel (From the Assessment of Dual Antiplatelet Therapy with Drug-Eluting Stents Study). The American Journal of Cardiology 2017;120:917-23. [DOI: 10.1016/j.amjcard.2017.06.019] [Cited by in Crossref: 10] [Cited by in F6Publishing: 7] [Article Influence: 2.5] [Reference Citation Analysis]
51 Yerasi C, Case BC, Forrestal BJ, Torguson R, Weintraub WS, Garcia-garcia HM, Waksman R. Optimizing Monotherapy Selection, Aspirin Versus P2Y12 Inhibitors, Following Percutaneous Coronary Intervention. The American Journal of Cardiology 2020;135:154-65. [DOI: 10.1016/j.amjcard.2020.07.061] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
52 Jiang M, You JHS. Cost-effectiveness analysis of 30-month vs 12-month dual antiplatelet therapy with clopidogrel and aspirin after drug-eluting stents in patients with acute coronary syndrome. Clin Cardiol 2017;40:789-96. [PMID: 28683175 DOI: 10.1002/clc.22756] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
53 Andrade JG, Deyell MW, Wong GC, Macle L. Antithrombotic Therapy for Atrial Fibrillation and Coronary Disease Demystified. Canadian Journal of Cardiology 2018;34:1426-36. [DOI: 10.1016/j.cjca.2018.08.028] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 2.7] [Reference Citation Analysis]
54 Wang HB, Zeng P, Yang J, Yang J, Liu XW. Paclitaxel-eluting stents versus sirolimus-eluting stents in patients with diabetes mellitus undergoing percutaneous coronary intervention: a systematic review and meta-analysis of randomized controlled trials. Intern Emerg Med 2016;11:1005-13. [PMID: 27631549 DOI: 10.1007/s11739-016-1529-0] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
55 Mehta SR, Bainey KR, Cantor WJ, Lordkipanidzé M, Marquis-Gravel G, Robinson SD, Sibbald M, So DY, Wong GC, Abunassar JG, Ackman ML, Bell AD, Cartier R, Douketis JD, Lawler PR, McMurtry MS, Udell JA, van Diepen S, Verma S, Mancini GBJ, Cairns JA, Tanguay JF; members of the Secondary Panel. 2018 Canadian Cardiovascular Society/Canadian Association of Interventional Cardiology Focused Update of the Guidelines for the Use of Antiplatelet Therapy. Can J Cardiol 2018;34:214-33. [PMID: 29475527 DOI: 10.1016/j.cjca.2017.12.012] [Cited by in Crossref: 107] [Cited by in F6Publishing: 62] [Article Influence: 26.8] [Reference Citation Analysis]
56 Kodaira M, Sawano M, Tanaka M, Kuno T, Numasawa Y, Ueda I, Fukuda K, Kohsaka S. Female sex as an independent predictor of high bleeding risk among East Asian percutaneous coronary intervention patients: A sex difference analysis. J Cardiol 2021:S0914-5087(21)00139-8. [PMID: 34172350 DOI: 10.1016/j.jjcc.2021.05.016] [Reference Citation Analysis]
57 Wang HY, Wang Y, Yin D, Gao RL, Yang YJ, Xu B, Dou KF. Percutaneous Coronary Intervention Complexity and Risk of Adverse Events in relation to High Bleeding Risk among Patients Receiving Drug-Eluting Stents: Insights from a Large Single-Center Cohort Study. J Interv Cardiol 2020;2020:2985435. [PMID: 32405273 DOI: 10.1155/2020/2985435] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
58 Raposeiras-roubín S, Caneiro Queija B, D’ascenzo F, Kinnaird T, Ariza-solé A, Manzano-fernández S, Templin C, Velicki L, Xanthopoulou I, Cerrato E, Quadri G, Rognoni A, Boccuzzi G, Montabone A, Taha S, Durante A, Gili S, Magnani G, Autelli M, Grosso A, Flores Blanco P, Garay A, Varbella F, Tomassini F, Cobas Paz R, Cespón Fernández M, Muñoz Pousa I, Gallo D, Morbiducci U, Domínguez-rodríguez A, Baz-alonso JA, Calvo-iglesias F, Valdés M, Cequier Á, Gaita F, Alexopoulos D, Íñiguez-romo A, Abu-assi E. Utilidad de la puntuación PARIS para evaluar el equilibrio isquémico-hemorrágico con ticagrelor y prasugrel tras un síndrome coronario agudo. Revista Española de Cardiología 2019;72:215-23. [DOI: 10.1016/j.recesp.2018.02.008] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
59 Kim DY, Cho SW, Park KT, Ahn JH, Park TK, Jang YH, Choi KH, Lee JM, Yang JH, Song YB, Choi JH, Choi SH, Gwon HC, Lee SH, Hahn JY. Long-term Outcomes of Clopidogrel Monotherapy versus Prolonged Dual Antiplatelet Therapy beyond 12 Months after Percutaneous Coronary Intervention in High-risk Patients. J Korean Med Sci 2021;36:e106. [PMID: 33904262 DOI: 10.3346/jkms.2021.36.e106] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
60 Vidula MK, McCarthy CP, Butala NM, Kennedy KF, Wasfy JH, Yeh RW, Secemsky EA. Causes and predictors of early readmission after percutaneous coronary intervention among patients discharged on oral anticoagulant therapy. PLoS One 2018;13:e0205457. [PMID: 30379868 DOI: 10.1371/journal.pone.0205457] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
61 Ko SQ, Valsdottir LR, Strom JB, Cheng YC, Hirayama A, Liu PH, Yanagisawa N, Yen H, Shen C, Yeh RW. Meta-Analysis of Bleeding Risk Prediction Scores in Patients After Percutaneous Coronary Intervention on Dual Antiplatelet Therapy. Am J Cardiol 2018;122:1843-52. [PMID: 30309627 DOI: 10.1016/j.amjcard.2018.08.025] [Cited by in Crossref: 8] [Cited by in F6Publishing: 4] [Article Influence: 2.7] [Reference Citation Analysis]
62 Kwok CS, Wong CW, Kontopantelis E, Barac A, Brown SA, Velagapudi P, Hilliard AA, Bharadwaj AS, Chadi Alraies M, Mohamed M, Bhatt DL, Mamas MA. Percutaneous coronary intervention in patients with cancer and readmissions within 90 days for acute myocardial infarction and bleeding in the USA. Eur Heart J 2021;42:1019-34. [PMID: 33681960 DOI: 10.1093/eurheartj/ehaa1032] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 9.0] [Reference Citation Analysis]
63 Marazzato J, Verdecchia P, Golino M, Blasi F, Crippa M, De Ponti R, Angeli F. An update on antithrombotic therapy in atrial fibrillation patients in long-term ambulatory setting after percutaneous coronary intervention: where do we go from here? Expert Opin Pharmacother 2021;:1-19. [PMID: 34074195 DOI: 10.1080/14656566.2021.1937119] [Reference Citation Analysis]
64 Natsuaki M, Morimoto T, Shiomi H, Yamaji K, Watanabe H, Shizuta S, Kato T, Ando K, Nakagawa Y, Furukawa Y, Tada T, Nagao K, Kadota K, Toyofuku M, Kimura T; on behalf of the CREDO-Kyoto PCI/CABG Registry Cohort-2 Investigators. Application of the Academic Research Consortium High Bleeding Risk Criteria in an All-Comers Registry of Percutaneous Coronary Intervention. Circ: Cardiovascular Interventions 2019;12. [DOI: 10.1161/circinterventions.119.008307] [Cited by in Crossref: 51] [Cited by in F6Publishing: 5] [Article Influence: 25.5] [Reference Citation Analysis]
65 Jang JY, Shin DH, Kim JS, Hong SJ, Ahn CM, Kim BK, Ko YG, Choi D, Hong MK, Park KW, Gwon HC, Kim HS, Jang Y. Optimal duration of DAPT after second-generation drug-eluting stent in acute coronary syndrome. PLoS One 2018;13:e0207386. [PMID: 30475845 DOI: 10.1371/journal.pone.0207386] [Cited by in Crossref: 9] [Cited by in F6Publishing: 5] [Article Influence: 3.0] [Reference Citation Analysis]
66 Moon JY, Franchi F, Rollini F, Angiolillo DJ. The quest for safer antithrombotic treatment regimens in patients with coronary artery disease: new strategies and paradigm shifts. Expert Review of Hematology 2017;11:5-12. [DOI: 10.1080/17474086.2018.1400378] [Cited by in Crossref: 15] [Cited by in F6Publishing: 12] [Article Influence: 3.8] [Reference Citation Analysis]
67 Cordero A, Rodriguez-manero M, García-acuña JM, López-palop R, Cid B, Carrillo P, Agra-bermejo R, González-salvado V, Iglesias-alvarez D, Bertomeu-martínez V, González-juanatey JR. Additive value of the CRUSADE score to the GRACE score for mortality risk prediction in patients with acute coronary syndromes. International Journal of Cardiology 2017;245:1-5. [DOI: 10.1016/j.ijcard.2017.07.095] [Cited by in Crossref: 13] [Cited by in F6Publishing: 8] [Article Influence: 3.3] [Reference Citation Analysis]
68 Bianco M, D'ascenzo F, Raposeiras Roubin S, Kinnaird T, Peyracchia M, Ariza-solé A, Cerrato E, Manzano-fernández S, Gravinese C, Templin C, Destefanis P, Velicki L, Luciano A, Xanthopoulou I, Rinaldi M, Rognoni A, Varbella F, Boccuzzi G, Omedè P, Montabone A, Bernardi A, Taha S, Rossini R, Durante A, Gili S, Magnani G, Autelli M, Grosso A, Blanco PF, Giustetto C, Garay A, Quadri G, Queija BC, Srdanovic I, Paz RC, Fernández MC, Pousa IM, Gallo D, Morbiducci U, Dominguez-rodriguez A, Lopez-cuenca Á, Cequier A, Alexopoulos D, Iñiguez-romo A, Pozzi R, Assi EA, Valgimigli M. Comparative external validation of the PRECISE-DAPT and PARIS risk scores in 4424 acute coronary syndrome patients treated with prasugrel or ticagrelor. International Journal of Cardiology 2020;301:200-6. [DOI: 10.1016/j.ijcard.2019.11.132] [Cited by in Crossref: 12] [Cited by in F6Publishing: 9] [Article Influence: 12.0] [Reference Citation Analysis]
69 Hinkel R, Howe A, Renner S, Ng J, Lee S, Klett K, Kaczmarek V, Moretti A, Laugwitz KL, Skroblin P, Mayr M, Milting H, Dendorfer A, Reichart B, Wolf E, Kupatt C. Diabetes Mellitus-Induced Microvascular Destabilization in the Myocardium. J Am Coll Cardiol. 2017;69:131-143. [PMID: 28081822 DOI: 10.1016/j.jacc.2016.10.058] [Cited by in Crossref: 73] [Cited by in F6Publishing: 60] [Article Influence: 18.3] [Reference Citation Analysis]
70 de Winter RJ, Chandrasekhar J, Kalkman DN, Aquino MB, Woudstra P, Beijk MA, Sartori S, Baber U, Tijssen JG, Koch KT, Dangas GD, Colombo A, Mehran R, Colombo A, Mehran R, Ong TK, Lee M, Iniguez A, Rowland S, Ghodsi N, Marx S, Distefano D, Weinberger J, Wong SC, Darrow B, Kaufman D, Milstein M, Mehran R, Chandrasekhar J, Baber U, Aquino M, Sartori S, Snyder C, Franklin-bond T, Cha JY, Vandertie L, Whittaker E, Allen K, Vogel B, Farhan S, Sorrentino S, Ge Z, Carlier M, Pourbaix S, Borisov B, Atzev B, Vasilev D, Christou C, Pešl L, Coufal Z, Kala P, Jeřábek P, Hájek P, Schee A, Ondrejcak R, Rozsíval V, Matějka J, Mates M, Khashaba A, Warda H, Margus S, Yan B, Lam CS, Chung TS, Tam LW, Chan AKC, Tsui PT, Tsui KL, Santoso T, Munawar M, Syukri M, Sinaga DA, Lupi A, Briguori C, Maskon O, Ong TK, Kazim S, Lee CY, Liew HB, Ali RM, Singh R, Den Heijer P, Wojcik J, Vukčević V, Hudec M, Farkaš A, Juhás S, Jankajová M, Dragula M, Cuellas Ramon C, Iniguez A, Tejedor P, Ruiz-poveda FL, Bosco AT, Boughzela E, Slim M, Haouala H, Lahidheb D, Boujnah MR, Goode GK, Dhamrait S, Gerber R, Clifford P, Kinnaird T, Varnagy G, Aguiar R. PJ, Huynh TV, Menown IB, den Heijer P, van't Hof AW, Erglis A, Suryapranata H, Arkenbout KE, Iñiguez A, Muller P, Tijssen J, de Winter RJ, Beijk MA, Koch K, Woudstra P, Kalkman DN. 1-Year Clinical Outcomes of All-Comer Patients Treated With the Dual-Therapy COMBO Stent. JACC: Cardiovascular Interventions 2018;11:1969-78. [DOI: 10.1016/j.jcin.2018.04.038] [Cited by in Crossref: 15] [Cited by in F6Publishing: 9] [Article Influence: 5.0] [Reference Citation Analysis]
71 Saito Y, Kobayashi Y. Update on Antithrombotic Therapy after Percutaneous Coronary Intervention. Intern Med 2020;59:311-21. [PMID: 31588089 DOI: 10.2169/internalmedicine.3685-19] [Cited by in Crossref: 9] [Cited by in F6Publishing: 4] [Article Influence: 4.5] [Reference Citation Analysis]
72 Bonello L, Laine M, Frere C. Platelet Reactivity: Back to the Future? JACC Cardiovasc Interv 2017;10:1618-20. [PMID: 28780026 DOI: 10.1016/j.jcin.2017.06.051] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
73 Chandrasekhar J, Baber U, Sartori S, Aquino M, Kini AS, Rao S, Weintraub W, Henry TD, Farhan S, Vogel B, Sorrentino S, Ge Z, Kapadia S, Muhlestein JB, Weiss S, Strauss C, Toma C, Defranco A, Effron MB, Keller S, Baker BA, Pocock S, Dangas G, Mehran R. Associations Between Complex PCI and Prasugrel or Clopidogrel Use in Patients With Acute Coronary Syndrome Who Undergo PCI: From the PROMETHEUS Study. Canadian Journal of Cardiology 2018;34:319-29. [DOI: 10.1016/j.cjca.2017.12.023] [Cited by in Crossref: 15] [Cited by in F6Publishing: 8] [Article Influence: 5.0] [Reference Citation Analysis]
74 Raposeiras-roubín S, Faxén J, Íñiguez-romo A, Henriques JPS, D'ascenzo F, Saucedo J, Szummer K, Jernberg T, James SK, Juanatey JRG, Wilton SB, Kikkert WJ, Nuñez-gil I, Ariza-sole A, Song X, Alexopoulos D, Liebetrau C, Kawaji T, Moretti C, Huczek Z, Nie S, Fujii T, Correia L, Kawashiri M, Caneiro-queija B, Cobas-paz R, Acuña JMG, Southern D, Alfonso E, Terol B, Garay A, Zhang D, Chen Y, Xanthopoulou I, Osman N, Möllmann H, Shiomi H, Giordana F, Gaita F, Kowara M, Filipiak K, Wang X, Yan Y, Fan J, Ikari Y, Nakahayshi T, Sakata K, Yamagishi M, Kalpak O, Kedev S, Rivera-asenjo D, Abu-assi E. Development and external validation of a post-discharge bleeding risk score in patients with acute coronary syndrome: The BleeMACS score. International Journal of Cardiology 2018;254:10-5. [DOI: 10.1016/j.ijcard.2017.10.103] [Cited by in Crossref: 39] [Cited by in F6Publishing: 18] [Article Influence: 13.0] [Reference Citation Analysis]
75 Saito Y, Kobayashi Y. Update on Antithrombotic Therapy after Percutaneous Coronary Intervention.Intern Med. 2020;59:311-321. [PMID: 31588089 DOI: 10.2169/internalmedicine.3685-3719] [Reference Citation Analysis]
76 Nakanishi N, Kaikita K, Ishii M, Kuyama N, Tabata N, Ito M, Yamanaga K, Fujisue K, Hoshiyama T, Kanazawa H, Hanatani S, Sueta D, Takashio S, Arima Y, Araki S, Usuku H, Nakamura T, Suzuki S, Yamamoto E, Soejima H, Matsushita K, Tsujita K. Development and assessment of total thrombus-formation analysis system-based bleeding risk model in patients undergoing percutaneous coronary intervention. Int J Cardiol 2021;325:121-6. [PMID: 33053391 DOI: 10.1016/j.ijcard.2020.10.015] [Cited by in Crossref: 2] [Article Influence: 2.0] [Reference Citation Analysis]
77 Chandrasekhar J, Sartori S, Aquino MB, Baber U, Hájek P, Atzev B, Hudec M, Ong TK, Mates M, Borisov B, Warda HM, den Heijer P, Wojcik J, Iniguez A, Coufal Z, Khashaba A, Schee A, Munawar M, Gerber RT, Yan BP, Tejedor P, Kala P, Liew HB, Lee M, Kalkman DN, Dangas GD, de Winter RJ, Colombo A, Mehran R; MASCOT investigators (Appendix I). Comparison of One-Year Outcomes in Patients >75 Versus ≤75 Years With Coronary Artery Disease Treated With COMBO Stents (From The MASCOT Registry).Am J Cardiol. 2020;127:1-8. [PMID: 32418717 DOI: 10.1016/j.amjcard.2020.04.014] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
78 Zhao XY, Li JX, Tang XF, Xu JJ, Song Y, Jiang L, Chen J, Song L, Gao LJ, Gao Z, Qiao SB, Yang YJ, Gao RL, Xu B, Yuan JQ. Validation of Predictive Value of Patterns of Nonadherence to Antiplatelet Regimen in Stented Patients Thrombotic Risk Score in Chinese Population Undergoing Percutaneous Coronary Intervention: A Prospective Observational Study. Chin Med J (Engl) 2018;131:2699-704. [PMID: 30425196 DOI: 10.4103/0366-6999.245263] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.5] [Reference Citation Analysis]
79 Wilson SJ, Newby DE, Dawson D, Irving J, Berry C. Duration of dual antiplatelet therapy in acute coronary syndrome. Heart 2017;103:573-80. [PMID: 28249994 DOI: 10.1136/heartjnl-2016-309871] [Cited by in Crossref: 20] [Cited by in F6Publishing: 14] [Article Influence: 5.0] [Reference Citation Analysis]
80 Toyota T, Morimoto T, Yamashita Y, Shiomi H, Kato T, Makiyama T, Nakagawa Y, Saito N, Shizuta S, Ono K, Kimura T. More- Versus Less-Intensive Lipid-Lowering Therapy: Systematic Review and Meta-Analysis. Circ: Cardiovascular Quality and Outcomes 2019;12. [DOI: 10.1161/circoutcomes.118.005460] [Cited by in Crossref: 3] [Article Influence: 1.5] [Reference Citation Analysis]
81 Chandrasekhar J, Dangas G, Baber U, Sartori S, Qadeer A, Aquino M, Vogel B, Faggioni M, Vijay P, Claessen BE, Goel R, Moreno P, Krishnan P, Kovacic JC, Kini A, Mehran R, Sharma S. Impact of insulin treated and non‐insulin‐treated diabetes compared to patients without diabetes on 1‐year outcomes following contemporary PCI. Catheter Cardiovasc Interv 2020;96:298-308. [DOI: 10.1002/ccd.28841] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 5.0] [Reference Citation Analysis]
82 Nakamura M, Kadota K, Takahashi A, Kanda J, Anzai H, Ishii Y, Shibata Y, Yasaka Y, Takamisawa I, Yamaguchi J, Takeda Y, Harada A, Motohashi T, Iijima R, Uemura S, Murakami Y; PENDULUM Registry Investigators*. Relationship Between Platelet Reactivity and Ischemic and Bleeding Events After Percutaneous Coronary Intervention in East Asian Patients: 1-Year Results of the PENDULUM Registry. J Am Heart Assoc 2020;9:e015439. [PMID: 32394794 DOI: 10.1161/JAHA.119.015439] [Cited by in Crossref: 8] [Cited by in F6Publishing: 3] [Article Influence: 8.0] [Reference Citation Analysis]
83 Moon JY, Franchi F, Rollini F, Angiolillo DJ. Evolution of Coronary Stent Technology and Implications for Duration of Dual Antiplatelet Therapy. Progress in Cardiovascular Diseases 2018;60:478-90. [DOI: 10.1016/j.pcad.2017.12.004] [Cited by in Crossref: 34] [Cited by in F6Publishing: 22] [Article Influence: 11.3] [Reference Citation Analysis]
84 Sim DS, Jeong MH, Kim HS, Gwon HC, Seung KB, Rha SW, Chae SC, Kim CJ, Cha KS, Park JS, Yoon JH, Chae JK, Joo SJ, Choi DJ, Hur SH, Seong IW, Cho MC, Kim DI, Oh SK, Ahn TH, Hwang JY. Utility of GRACE and ACUITY-HORIZONS risk scores to guide dual antiplatelet therapy in Korean patients with acute myocardial infarction undergoing drug-eluting stenting. Journal of Cardiology 2018;72:411-9. [DOI: 10.1016/j.jjcc.2018.04.006] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
85 Costa F, Windecker S, Valgimigli M. Dual Antiplatelet Therapy Duration: Reconciling the Inconsistencies. Drugs 2017;77:1733-54. [PMID: 28853033 DOI: 10.1007/s40265-017-0806-1] [Cited by in Crossref: 13] [Cited by in F6Publishing: 8] [Article Influence: 4.3] [Reference Citation Analysis]
86 Howard CE, Nambi V, Jneid H, Khalid U. Extended Duration of Dual-Antiplatelet Therapy After Percutaneous Coronary Intervention: How Long Is Too Long? J Am Heart Assoc 2019;8:e012639. [PMID: 31576769 DOI: 10.1161/JAHA.119.012639] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 2.5] [Reference Citation Analysis]
87 Gallone G, Baldetti L, Pagnesi M, Latib A, Colombo A, Libby P, Giannini F. Medical Therapy for Long-Term Prevention of Atherothrombosis Following an Acute Coronary Syndrome: JACC State-of-the-Art Review. J Am Coll Cardiol 2018;72:2886-903. [PMID: 30522652 DOI: 10.1016/j.jacc.2018.09.052] [Cited by in Crossref: 30] [Cited by in F6Publishing: 19] [Article Influence: 15.0] [Reference Citation Analysis]
88 Natsuaki M, Morimoto T, Watanabe H, Nakagawa Y, Furukawa Y, Kadota K, Akasaka T, Hanaoka KI, Kozuma K, Tanabe K, Morino Y, Muramatsu T, Kimura T; CREDO‐Kyoto PCI/CABG registry cohort‐2, RESET and NEXT trial investigators. Ischemic and Bleeding Risk After Percutaneous Coronary Intervention in Patients With Prior Ischemic and Hemorrhagic Stroke. J Am Heart Assoc 2019;8:e013356. [PMID: 31701821 DOI: 10.1161/JAHA.119.013356] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
89 Lemesle G, Meurice T, Tricot O, Lamblin N, Bauters C. Association of Diabetic Status and Glycemic Control With Ischemic and Bleeding Outcomes in Patients With Stable Coronary Artery Disease: The 5-Year CORONOR Registry. J Am Heart Assoc 2018;7:e008354. [PMID: 29728374 DOI: 10.1161/JAHA.117.008354] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
90 Valgimigli M, Bueno H, Byrne RA, Collet J, Costa F, Jeppsson A, Jüni P, Kastrati A, Kolh P, Mauri L, Montalescot G, Neumann F, Petricevic M, Roffi M, Steg PG, Windecker S, Zamorano JL, Levine GN, Badimon L, Vranckx P, Agewall S, Andreotti F, Antman E, Barbato E, Bassand J, Bugiardini R, Cikirikcioglu M, Cuisset T, De Bonis M, Delgado V, Fitzsimons D, Gaemperli O, Galiè N, Gilard M, Hamm CW, Ibanez B, Iung B, James S, Knuuti J, Landmesser U, Leclercq C, Lettino M, Lip G, Piepoli MF, Pierard L, Schwerzmann M, Sechtem U, Simpson IA, Uva MS, Stabile E, Storey RF, Tendera M, Van de Werf F, Verheugt F, Aboyans V, Windecker S, Aboyans V, Agewall S, Barbato E, Bueno H, Coca A, Collet J, Coman IM, Dean V, Delgado V, Fitzsimons D, Gaemperli O, Hindricks G, Iung B, Jüni P, Katus HA, Knuuti J, Lancellotti P, Leclercq C, Mcdonagh T, Piepoli MF, Ponikowski P, Richter DJ, Roffi M, Shlyakhto E, Simpson IA, Zamorano JL, Windecker S, Aboyans V, Agewall S, Barbato E, Bueno H, Coca A, Collet J, Coman IM, Dean V, Delgado V, Fitzsimons D, Gaemperli O, Hindricks G, Iung B, Jüni P, Katus HA, Knuuti J, Lancellotti P, Leclercq C, Mcdonagh T, Piepoli MF, Ponikowski P, Richter DJ, Roffi M, Shlyakhto E, Simpson IA, Zamorano JL, Roithinger FX, Aliyev F, Stelmashok V, Desmet W, Postadzhiyan A, Georghiou GP, Motovska Z, Grove EL, Marandi T, Kiviniemi T, Kedev S, Gilard M, Massberg S, Alexopoulos D, Kiss RG, Gudmundsdottir IJ, Mcfadden EP, Lev E, De Luca L, Sugraliyev A, Haliti E, Mirrakhimov E, Latkovskis G, Petrauskiene B, Huijnen S, Magri CJ, Cherradi R, Ten Berg JM, Eritsland J, Budaj A, Aguiar CT, Duplyakov D, Zavatta M, Antonijevic NM, Motovska Z, Fras Z, Montoliu AT, Varenhorst C, Tsakiris D, Addad F, Aydogdu S, Parkhomenko A, Kinnaird T; ESC Scientific Document Group, ESC Committee for Practice Guidelines (CPG), ESC National Cardiac Societies. 2017 ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS. European Heart Journal 2018;39:213-60. [DOI: 10.1093/eurheartj/ehx419] [Cited by in Crossref: 1230] [Cited by in F6Publishing: 779] [Article Influence: 307.5] [Reference Citation Analysis]
91 Harada Y, Michel J, Lohaus R, Mayer K, Emmer R, Lena Lahmann A, Colleran R, Giacoppo D, Wolk A, Berg JMT, Neumann F, Han Y, Adriaenssens T, Tölg R, Seyfarth M, Maeng M, Zrenner B, Jacobshagen C, Wöhrle J, Kufner S, Morath T, Ibrahim T, Bernlochner I, Fischer M, Schunkert H, Laugwitz K, Mehilli J, A. Byrne R, Kastrati A, Schulz-schüpke S. Validation of the DAPT score in patients randomized to 6 or 12 months clopidogrel after predominantly second-generation drug-eluting stents. Thromb Haemost 2017;117:1989-99. [DOI: 10.1160/th17-02-0101] [Cited by in Crossref: 19] [Article Influence: 4.8] [Reference Citation Analysis]
92 Dangas G, Baber U, Sharma S, Giustino G, Mehta S, Cohen DJ, Angiolillo DJ, Sartori S, Chandiramani R, Briguori C, Dudek D, Escaned J, Huber K, Collier T, Kornowski R, Kunadian V, Kaul U, Oldroyd K, Sardella G, Shlofmitz R, Witzenbichler B, Ya-ling H, Pocock S, Gibson CM, Mehran R. Ticagrelor With or Without Aspirin After Complex PCI. Journal of the American College of Cardiology 2020;75:2414-24. [DOI: 10.1016/j.jacc.2020.03.011] [Cited by in Crossref: 47] [Cited by in F6Publishing: 27] [Article Influence: 47.0] [Reference Citation Analysis]
93 Baber U, Li SX, Pinnelas R, Pocock SJ, Krucoff MW, Ariti C, Gibson CM, Steg PG, Weisz G, Witzenbichler B, Henry TD, Kini AS, Stuckey T, Cohen DJ, Iakovou I, Dangas G, Aquino MB, Sartori S, Chieffo A, Moliterno DJ, Colombo A, Mehran R. Incidence, Patterns, and Impact of Dual Antiplatelet Therapy Cessation Among Patients With and Without Chronic Kidney Disease Undergoing Percutaneous Coronary Intervention: Results From the PARIS Registry (Patterns of Non-Adherence to Anti-Platelet Regimens in Stented Patients). Circ Cardiovasc Interv 2018;11:e006144. [PMID: 29870385 DOI: 10.1161/CIRCINTERVENTIONS.117.006144] [Cited by in Crossref: 13] [Cited by in F6Publishing: 2] [Article Influence: 6.5] [Reference Citation Analysis]
94 Horie K, Matsumoto T, Mizutani Y, Tada N, Osai N, Isawa T, Taguri M, Kato S, Honda T, Ootomo T, Inoue N. A prospective interventional registry of short-term dual-antiplatelet treatment after implantation of drug-eluting stents in patients with atrial fibrillation requiring oral anticoagulation therapy. Cardiovasc Interv Ther 2020;35:150-61. [PMID: 31093885 DOI: 10.1007/s12928-019-00589-7] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
95 Castini D, Persampieri S, Sabatelli L, Erba M, Ferrante G, Valli F, Centola M, Carugo S. Utility of the HAS-BLED score for risk stratification of patients with acute coronary syndrome. Heart Vessels 2019;34:1621-30. [PMID: 30969359 DOI: 10.1007/s00380-019-01405-1] [Cited by in Crossref: 5] [Cited by in F6Publishing: 1] [Article Influence: 2.5] [Reference Citation Analysis]
96 Verdoia M, Camaro C, Kedhi E, Marcolongo M, Suryapranata H, De Luca G. Dual Antiplatelet Therapy Duration in Acute Coronary Syndrome Patients: The State of the Art and Open Issues. Cardiovasc Ther 2020;2020:6495036. [PMID: 32328172 DOI: 10.1155/2020/6495036] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
97 Zhang Y, Shao T, Yao L, Yue H, Zhang Z. Effects of tirofiban on stent thrombosis, Hs-CRP, IL-6 and sICAM-1 after PCI of acute myocardial infarction. Exp Ther Med 2018;16:3383-8. [PMID: 30233685 DOI: 10.3892/etm.2018.6589] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.7] [Reference Citation Analysis]
98 Ueki Y, Vögeli B, Karagiannis A, Zanchin T, Zanchin C, Rhyner D, Otsuka T, Praz F, Siontis GCM, Moro C, Stortecky S, Billinger M, Valgimigli M, Pilgrim T, Windecker S, Suter T, Räber L. Ischemia and Bleeding in Cancer Patients Undergoing Percutaneous Coronary Intervention. JACC CardioOncol 2019;1:145-55. [PMID: 34396175 DOI: 10.1016/j.jaccao.2019.11.001] [Cited by in Crossref: 5] [Cited by in F6Publishing: 1] [Article Influence: 2.5] [Reference Citation Analysis]
99 Capodanno D, Angiolillo DJ. Tailoring duration of DAPT with risk scores. The Lancet 2017;389:987-9. [DOI: 10.1016/s0140-6736(17)30591-3] [Cited by in Crossref: 31] [Cited by in F6Publishing: 7] [Article Influence: 7.8] [Reference Citation Analysis]
100 Brieger D, Pocock SJ, Blankenberg S, Chen JY, Cohen MG, Granger CB, Grieve R, Nicolau JC, Simon T, Westermann D, Yasuda S, Gregson J, Rennie KL, Hedman K, Sundell KA, Goodman SG. Two-year outcomes among stable high-risk patients following acute MI. Insights from a global registry in 25 countries. Int J Cardiol 2020;311:7-14. [PMID: 32057476 DOI: 10.1016/j.ijcard.2020.01.070] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
101 Buccheri S, D'Arrigo P, Franchina G, Capodanno D. Risk Stratification in Patients with Coronary Artery Disease: A Practical Walkthrough in the Landscape of Prognostic Risk Models. Interv Cardiol 2018;13:112-20. [PMID: 30443266 DOI: 10.15420/icr.2018.16.2] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 3.7] [Reference Citation Analysis]
102 Cuisset T, Verheugt FWA, Mauri L. Update on antithrombotic therapy after percutaneous coronary revascularisation. The Lancet 2017;390:810-20. [DOI: 10.1016/s0140-6736(17)31936-0] [Cited by in Crossref: 16] [Cited by in F6Publishing: 2] [Article Influence: 4.0] [Reference Citation Analysis]
103 Sakamoto K, Sato R, Tabata N, Ishii M, Yamashita T, Nagamatsu S, Motozato K, Yamanaga K, Hokimoto S, Sueta D, Araki S, Fujisue K, Arima Y, Takashio S, Fujimoto K, Shimomura H, Tsunoda R, Hirose T, Sato K, Kikuta K, Sakaino N, Nakamura S, Yamamoto N, Matsumura T, Kajiwara I, Tayama S, Sakamoto T, Nakao K, Oshima S, Yamamoto E, Kaikita K, Tsujita K; Kumamoto Intervention Conference Study (KICS) Investigators. Temporal trends in coronary intervention strategies and the impact on one-year clinical events: data from a Japanese multi-center real-world cohort study. Cardiovasc Interv Ther 2021. [PMID: 33421026 DOI: 10.1007/s12928-020-00752-5] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
104 Chan Pin Yin D, Azzahhafi J, James S. Risk Assessment Using Risk Scores in Patients with Acute Coronary Syndrome. J Clin Med 2020;9:E3039. [PMID: 32967247 DOI: 10.3390/jcm9093039] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
105 Costa F, van Klaveren D, James S, Heg D, Räber L, Feres F, Pilgrim T, Hong MK, Kim HS, Colombo A, Steg PG, Zanchin T, Palmerini T, Wallentin L, Bhatt DL, Stone GW, Windecker S, Steyerberg EW, Valgimigli M; PRECISE-DAPT Study Investigators. Derivation and validation of the predicting bleeding complications in patients undergoing stent implantation and subsequent dual antiplatelet therapy (PRECISE-DAPT) score: a pooled analysis of individual-patient datasets from clinical trials. Lancet 2017;389:1025-34. [PMID: 28290994 DOI: 10.1016/S0140-6736(17)30397-5] [Cited by in Crossref: 468] [Cited by in F6Publishing: 92] [Article Influence: 156.0] [Reference Citation Analysis]
106 Sorrentino S, Claessen BE, Chandiramani R, Guedeney P, Vogel B, Baber U, Rau V, Wang J, Krucoff M, Kozuma K, Ge J, Seth A, Makkar R, Liu Y, Bangalore S, Bhatt DL, Angiolillo DJ, Saito S, Neumann F, Hermiller J, Valgimigli M, Mehran R. Long-Term Safety and Efficacy of Durable Polymer Cobalt-Chromium Everolimus-Eluting Stents in Patients at High Bleeding Risk: A Patient-Level Stratified Analysis From Four Postapproval Studies. Circulation 2020;141:891-901. [DOI: 10.1161/circulationaha.119.041619] [Cited by in Crossref: 16] [Article Influence: 16.0] [Reference Citation Analysis]
107 Ueki Y, Karagiannis A, Zanchin C, Zanchin T, Stortecky S, Koskinas KC, Siontis GC, Praz F, Otsuka T, Hunziker L, Heg D, Moschovitis A, Seiler C, Billinger M, Pilgrim T, Valgimigli M, Windecker S, Räber L. Validation of High-Risk Features for Stent-Related Ischemic Events as Endorsed by the 2017 DAPT Guidelines. JACC: Cardiovascular Interventions 2019;12:820-30. [DOI: 10.1016/j.jcin.2018.12.005] [Cited by in Crossref: 20] [Cited by in F6Publishing: 9] [Article Influence: 10.0] [Reference Citation Analysis]
108 Qian J, Zan J, Kuang L, Che L, Yu Y, Shen T, Tang J, Chen F, Liu X. A predictive nomogram of bleeding risk in patients with atrial fibrillation after drug-eluting stent implantation. Ann Transl Med 2021;9:193. [PMID: 33708820 DOI: 10.21037/atm-20-3971] [Reference Citation Analysis]
109 Raposeiras-Roubín S, Caneiro Queija B, D'Ascenzo F, Kinnaird T, Ariza-Solé A, Manzano-Fernández S, Templin C, Velicki L, Xanthopoulou I, Cerrato E, Quadri G, Rognoni A, Boccuzzi G, Montabone A, Taha S, Durante A, Gili S, Magnani G, Autelli M, Grosso A, Flores Blanco P, Garay A, Varbella F, Tomassini F, Cobas Paz R, Cespón Fernández M, Muñoz Pousa I, Gallo D, Morbiducci U, Domínguez-Rodríguez A, Baz-Alonso JA, Calvo-Iglesias F, Valdés M, Cequier Á, Gaita F, Alexopoulos D, Íñiguez-Romo A, Abu-Assi E. Usefulness of the PARIS Score to Evaluate the Ischemic-hemorrhagic Net Benefit With Ticagrelor and Prasugrel After an Acute Coronary Syndrome. Rev Esp Cardiol (Engl Ed) 2019;72:215-23. [PMID: 30029980 DOI: 10.1016/j.rec.2018.06.004] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.7] [Reference Citation Analysis]
110 Covic A, Genovesi S, Rossignol P, Kalra PA, Ortiz A, Banach M, Burlacu A. Practical issues in clinical scenarios involving CKD patients requiring antithrombotic therapy in light of the 2017 ESC guideline recommendations. BMC Med 2018;16:158. [PMID: 30227855 DOI: 10.1186/s12916-018-1145-0] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 2.7] [Reference Citation Analysis]
111 Chichareon P, Modolo R, Kogame N, Takahashi K, Chang C, Tomaniak M, Botelho R, Eeckhout E, Hofma S, Trendafilova-lazarova D, Kőszegi Z, Iñiguez A, Wykrzykowska JJ, Piek JJ, Garg S, Hamm C, Steg PG, Jüni P, Vranckx P, Valgimigli M, Windecker S, Onuma Y, Serruys PW. Association of diabetes with outcomes in patients undergoing contemporary percutaneous coronary intervention: Pre-specified subgroup analysis from the randomized GLOBAL LEADERS study. Atherosclerosis 2020;295:45-53. [DOI: 10.1016/j.atherosclerosis.2020.01.002] [Cited by in Crossref: 15] [Cited by in F6Publishing: 11] [Article Influence: 15.0] [Reference Citation Analysis]
112 Guedeney P, Sorrentino S, Claessen B, Mehran R. The link between anemia and adverse outcomes in patients with acute coronary syndrome. Expert Review of Cardiovascular Therapy 2018;17:151-9. [DOI: 10.1080/14779072.2019.1575729] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
113 Baber U, Leisman DE, Cohen DJ, Gibson CM, Henry TD, Dangas G, Moliterno D, Kini A, Krucoff M, Colombo A, Chieffo A, Sartori S, Witzenbichler B, Steg PG, Pocock SJ, Mehran R. Tailoring Antiplatelet Therapy Intensity to Ischemic and Bleeding Risk. Circ Cardiovasc Qual Outcomes 2019;12:e004945. [PMID: 30606052 DOI: 10.1161/CIRCOUTCOMES.118.004945] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 4.0] [Reference Citation Analysis]
114 van der Sangen NMR, Rozemeijer R, Chan Pin Yin DRPP, Valgimigli M, Windecker S, James SK, Buccheri S, Ten Berg JM, Henriques JPS, Voskuil M, Kikkert WJ. Patient-tailored antithrombotic therapy following percutaneous coronary intervention. Eur Heart J 2021;42:1038-46. [PMID: 33515031 DOI: 10.1093/eurheartj/ehaa1097] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
115 Pavasini R, Maietti E, Tonet E, Bugani G, Tebaldi M, Biscaglia S, Cimaglia P, Serenelli M, Ruggiero R, Vitali F, Galvani M, Minarelli M, Rubboli A, Bernucci D, Volpato S, Campo G. Bleeding Risk Scores and Scales of Frailty for the Prediction of Haemorrhagic Events in Older Adults with Acute Coronary Syndrome: Insights from the FRASER study. Cardiovasc Drugs Ther 2019;33:523-32. [PMID: 31549262 DOI: 10.1007/s10557-019-06911-y] [Cited by in Crossref: 7] [Cited by in F6Publishing: 3] [Article Influence: 7.0] [Reference Citation Analysis]
116 Ford TJ, Khan A, Docherty KF, Jackson A, Morrow A, Sidik N, Rocchiccioli P, Good R, Eteiba H, Watkins S, Shaukat A, Lindsay M, Robertson K, Petrie M, Berry C, Oldroyd KG, McEntegart M. Sex differences in procedural and clinical outcomes following rotational atherectomy. Catheter Cardiovasc Interv 2020;95:232-41. [PMID: 31264314 DOI: 10.1002/ccd.28373] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 2.5] [Reference Citation Analysis]
117 Guedeney P, Sorrentino S, Vogel B, Baber U, Claessen BE, Mehran R. Assessing and minimizing the risk of percutaneous coronary intervention in patients with chronic kidney disease. Expert Review of Cardiovascular Therapy 2018;16:825-35. [DOI: 10.1080/14779072.2018.1526082] [Cited by in Crossref: 10] [Cited by in F6Publishing: 4] [Article Influence: 3.3] [Reference Citation Analysis]
118 Bavishi C, Trivedi V, Singh M, Katz E, Messerli FH, Bangalore S. Duration of Dual Antiplatelet Therapy in Patients with an Acute Coronary Syndrome Undergoing Percutaneous Coronary Intervention. Am J Med 2017;130:1325.e1-1325.e12. [PMID: 28623176 DOI: 10.1016/j.amjmed.2017.05.029] [Cited by in Crossref: 11] [Cited by in F6Publishing: 6] [Article Influence: 2.8] [Reference Citation Analysis]
119 Faggioni M, Baber U, Sartori S, Giustino G, Cohen DJ, Henry TD, Farhan S, Ariti C, Dangas G, Gibson M, Giacoppo D, Krucoff MW, Aquino M, Chandrasekhar J, Moliterno DJ, Colombo A, Vogel B, Chieffo A, Kini AS, Witzenbichler B, Weisz G, Steg PG, Pocock S, Mehran R. Incidence, Patterns, and Associations Between Dual-Antiplatelet Therapy Cessation and Risk for Adverse Events Among Patients With and Without Diabetes Mellitus Receiving Drug-Eluting Stents. JACC: Cardiovascular Interventions 2017;10:645-54. [DOI: 10.1016/j.jcin.2016.12.003] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 3.8] [Reference Citation Analysis]
120 Spinthakis N, Farag M, Rocca B, Gorog DA. More, More, More: Reducing Thrombosis in Acute Coronary Syndromes Beyond Dual Antiplatelet Therapy-Current Data and Future Directions. J Am Heart Assoc 2018;7:e007754. [PMID: 29374045 DOI: 10.1161/JAHA.117.007754] [Cited by in Crossref: 9] [Cited by in F6Publishing: 5] [Article Influence: 3.0] [Reference Citation Analysis]
121 Mavrakanas TA, Chatzizisis YS, Gariani K, Kereiakes DJ, Gargiulo G, Helft G, Gilard M, Feres F, Costa RA, Morice MC, Georges JL, Valgimigli M, Bhatt DL, Mauri L, Charytan DM. Duration of Dual Antiplatelet Therapy in Patients with CKD and Drug-Eluting Stents: A Meta-Analysis. Clin J Am Soc Nephrol 2019;14:810-22. [PMID: 31010936 DOI: 10.2215/CJN.12901018] [Cited by in Crossref: 6] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
122 Tersalvi G, Biasco L, Cioffi GM, Pedrazzini G. Acute Coronary Syndrome, Antiplatelet Therapy, and Bleeding: A Clinical Perspective. J Clin Med 2020;9:E2064. [PMID: 32630233 DOI: 10.3390/jcm9072064] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 5.0] [Reference Citation Analysis]
123 Gargiulo G, Patialiakas A, Piccolo R, Thury A, Colangelo S, Campo G, Tebaldi M, Ungi I, Tondi S, Roffi M, Menozzi A, de Cesare N, Garbo R, Meliga E, Testa L, Gabriel HM, Ferlini M, Liistro F, Dellavalle A, Vranckx P, Briguori C, Windecker S, Valgimigli M. Impact of angiographic coronary artery disease complexity on ischemic and bleeding risks and on the comparative effectiveness of zotarolimus-eluting vs. bare-metal stents in uncertain drug-eluting stent candidates. Int J Cardiol 2019;277:60-5. [PMID: 30293666 DOI: 10.1016/j.ijcard.2018.09.120] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.7] [Reference Citation Analysis]
124 Kao CC, Wu MS, Chuang MT, Lin YC, Huang CY, Chang WC, Chen CW, Chang TH. Investigation of dual antiplatelet therapy after coronary stenting in patients with chronic kidney disease. PLoS One 2021;16:e0255645. [PMID: 34347826 DOI: 10.1371/journal.pone.0255645] [Reference Citation Analysis]
125 Chen Y, Yin T, Xi S, Zhang S, Yan H, Tang Y, Qian J, Chen J, Su X, Du Z, Wang L, Qin Q, Gao C, Zheng Y, Zhao X, Cheng X, Li Z, Zhang W, Chen H, Wang J, Yang Z, Li H, Liu H, Zhou X, Qu B, Xiang D, Guo Y, Wang L, Nie S, Fu G, Yang M, Cai S. A risk score to predict postdischarge bleeding among acute coronary syndrome patients undergoing percutaneous coronary intervention: BRIC-ACS study. Catheter Cardiovasc Interv 2019;93:1194-204. [PMID: 31112635 DOI: 10.1002/ccd.28325] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
126 Cai A, Dillon C, Hillegass WB, Beasley M, Brott BC, Bittner VA, Perry GJ, Halade GV, Prabhu SD, Limdi NA. Risk of Major Adverse Cardiovascular Events and Major Hemorrhage Among White and Black Patients Undergoing Percutaneous Coronary Intervention. J Am Heart Assoc 2019;8:e012874. [PMID: 31701784 DOI: 10.1161/JAHA.119.012874] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 3.5] [Reference Citation Analysis]
127 Montalto C, Crimi G, Morici N, Piatti L, Grosseto D, Sganzerla P, Tortorella G, De Rosa R, De Luca L, De Luca G, Palmerini T, Valgimigli M, Savonitto S, De Servi S. Bleeding risk prediction in elderly patients managed invasively for acute coronary syndromes: External validation of the PRECISE-DAPT and PARIS scores. Int J Cardiol 2021;328:22-8. [PMID: 33279593 DOI: 10.1016/j.ijcard.2020.11.065] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
128 Chandrasekhar J, Baber U, Sartori S, Aquino M, Tomey M, Kruckoff M, Moliterno D, Henry TD, Weisz G, Gibson CM, Iakovou I, Kini A, Faggioni M, Vogel B, Farhan S, Colombo A, Steg PG, Witzenbichler B, Chieffo A, Cohen D, Stuckey T, Ariti C, Pocock S, Dangas G, Mehran R. Patterns and associations between DAPT cessation and 2-year clinical outcomes in left main/proximal LAD versus other PCI: Results from the Patterns of Non-Adherence to Dual Antiplatelet Therapy in Stented Patients (PARIS) registry. International Journal of Cardiology 2017;243:132-9. [DOI: 10.1016/j.ijcard.2017.05.049] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
129 Varenne O, Cook S, Sideris G, Kedev S, Cuisset T, Carrié D, Hovasse T, Garot P, El Mahmoud R, Spaulding C, Helft G, Diaz Fernandez JF, Brugaletta S, Pinar-bermudez E, Mauri Ferre J, Commeau P, Teiger E, Bogaerts K, Sabate M, Morice M, Sinnaeve PR. Drug-eluting stents in elderly patients with coronary artery disease (SENIOR): a randomised single-blind trial. The Lancet 2018;391:41-50. [DOI: 10.1016/s0140-6736(17)32713-7] [Cited by in Crossref: 190] [Cited by in F6Publishing: 32] [Article Influence: 63.3] [Reference Citation Analysis]
130 Choi SY, Kim MH, Lee KM, Ko YG, Yoon CH, Jo MK, Yun SC. Comparison of Performance between ARC-HBR Criteria and PRECISE-DAPT Score in Patients Undergoing Percutaneous Coronary Intervention. J Clin Med 2021;10:2566. [PMID: 34200528 DOI: 10.3390/jcm10122566] [Reference Citation Analysis]
131 Park Y, Franchi F, Rollini F, Angiolillo DJ. Dual antiplatelet therapy after coronary stenting. Expert Opinion on Pharmacotherapy 2016;17:1775-87. [DOI: 10.1080/14656566.2016.1202924] [Cited by in Crossref: 10] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
132 Numasawa Y, Sawano M, Fukuoka R, Ejiri K, Kuno T, Shoji S, Kohsaka S. Antithrombotic Strategy for Patients with Acute Coronary Syndrome: A Perspective from East Asia. J Clin Med 2020;9:E1963. [PMID: 32585929 DOI: 10.3390/jcm9061963] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 6.0] [Reference Citation Analysis]
133 Vidula MK, Secemsky EA, Yeh RW. Duration of Dual Antiplatelet Therapy for Stented Patients: An Update for the Clinician. Progress in Cardiovascular Diseases 2018;60:491-9. [DOI: 10.1016/j.pcad.2018.01.006] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.7] [Reference Citation Analysis]
134 Cosentino N, Campodonico J, Faggiano P, De Metrio M, Rubino M, Milazzo V, Sbolli M, Perego C, Provini M, Bonomi A, Veglia F, Bartorelli AL, Marenzi G. A new score based on the PEGASUS-TIMI 54 criteria for risk stratification of patients with acute myocardial infarction. International Journal of Cardiology 2019;278:1-6. [DOI: 10.1016/j.ijcard.2018.11.142] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 2.5] [Reference Citation Analysis]
135 D'Ascenzo F, De Filippo O, Gallone G, Mittone G, Deriu MA, Iannaccone M, Ariza-Solé A, Liebetrau C, Manzano-Fernández S, Quadri G, Kinnaird T, Campo G, Simao Henriques JP, Hughes JM, Dominguez-Rodriguez A, Aldinucci M, Morbiducci U, Patti G, Raposeiras-Roubin S, Abu-Assi E, De Ferrari GM; PRAISE study group. Machine learning-based prediction of adverse events following an acute coronary syndrome (PRAISE): a modelling study of pooled datasets. Lancet 2021;397:199-207. [PMID: 33453782 DOI: 10.1016/S0140-6736(20)32519-8] [Cited by in Crossref: 15] [Cited by in F6Publishing: 3] [Article Influence: 15.0] [Reference Citation Analysis]
136 Crimi G, Morici N, Ferrario M, Ferri LA, Piatti L, Grosseto D, Cacucci M, Mandurino Mirizzi A, Toso A, Piscione F, De Carlo M, Elia LR, Trimarco B, Bolognese L, Bovenzi FM, De Luca G, Savonitto S, De Servi S. Time Course of Ischemic and Bleeding Burden in Elderly Patients With Acute Coronary Syndromes Randomized to Low-Dose Prasugrel or Clopidogrel. J Am Heart Assoc 2019;8:e010956. [PMID: 30636561 DOI: 10.1161/JAHA.118.010956] [Cited by in Crossref: 15] [Cited by in F6Publishing: 4] [Article Influence: 15.0] [Reference Citation Analysis]
137 Oana Darabont R, Stoicescu C, Tiu C. Therapeutic Challenges in Patients With Noncardioembolic Acute Ischemic Stroke in Need of Double Antiplatelet Therapy for Coronary Artery Disease. American Journal of Therapeutics 2019;26:e213-21. [DOI: 10.1097/mjt.0000000000000924] [Cited by in Crossref: 2] [Article Influence: 1.0] [Reference Citation Analysis]
138 Zeng Q, Zhang LD, Wang W. A meta-analysis of randomized controlled trials investigating tirofiban combined with conventional drugs by intracoronary administration for no-reflow prevention. Anatol J Cardiol 2021;25:7-16. [PMID: 33382055 DOI: 10.14744/AnatolJCardiol.2020.99469] [Reference Citation Analysis]
139 Chen H, Power D, Giustino G. Optimal duration of dual antiplatelet therapy after PCI: integrating procedural complexity, bleeding risk and the acuteness of clinical presentation. Expert Review of Cardiovascular Therapy 2018;16:735-48. [DOI: 10.1080/14779072.2018.1523718] [Cited by in Crossref: 7] [Cited by in F6Publishing: 3] [Article Influence: 2.3] [Reference Citation Analysis]
140 D'Ascenzo F, Barbero U, Abdirashid M, Trabattoni D, Boccuzzi G, Ryan N, Quadri G, Capodanno D, Venuti G, Muscoli S, Tomassini F, Autelli M, Montabone A, Wojakowski W, Rognoni A, Gallo D, Parma R, De Luca L, Figini F, Mitomo S, Montefusco A, Mattesini A, Wańha W, Protasiewicz M, Smolka G, Huczek Z, Rolfo C, Cortese B, Chieffo A, Kuliczowki W, Nuñez-Gil I, Morbiducci U, Ugo F, Marengo G, Iannaccone M, Cerrato E, Mario CD, Moretti C, D'Amico M, Varbella F, Lüscher TF, Sheiban I, Escaned J, Romeo F, Rinaldi M, De Ferrari GM, Helft G. Incidence of Adverse Events at 3 Months Versus at 12 Months After Dual Antiplatelet Therapy Cessation in Patients Treated With Thin Stents With Unprotected Left Main or Coronary Bifurcations. Am J Cardiol 2020;125:491-9. [PMID: 31889527 DOI: 10.1016/j.amjcard.2019.10.058] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 2.5] [Reference Citation Analysis]
141 Wang HY, Gao RL, Xu B, Yang YJ, Yin D, Wang Y, Dou KF. Benefit-risk profile of extended dual antiplatelet therapy beyond 1 year in patients with high risk of ischemic or bleeding events after PCI. Platelets 2021;32:533-41. [PMID: 32498587 DOI: 10.1080/09537104.2020.1774052] [Reference Citation Analysis]
142 Kanenawa K, Yamaji K, Tashiro H, Domei T, Ando K, Watanabe H, Kimura T. Patient Selection and Clinical Outcomes in the STOPDAPT-2 Trial: An All-Comer Single-Center Registry During the Enrollment Period of the STOPDAPT-2 Randomized Controlled Trial. Circ Cardiovasc Interv 2021;14:e010007. [PMID: 33541100 DOI: 10.1161/CIRCINTERVENTIONS.120.010007] [Cited by in Crossref: 2] [Article Influence: 2.0] [Reference Citation Analysis]
143 Fukaya H, Ako J. Bleeding risk score in Japanese patients on antiplatelets plus an anticoagulant. Journal of Cardiology 2019;73:466-7. [DOI: 10.1016/j.jjcc.2018.11.004] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
144 Baber U, Chandrasekhar J, Sartori S, Aquino M, Kini AS, Kapadia S, Weintraub W, Muhlestein JB, Vogel B, Faggioni M, Farhan S, Weiss S, Strauss C, Toma C, DeFranco A, Baker BA, Keller S, Effron MB, Henry TD, Rao S, Pocock S, Dangas G, Mehran R. Associations Between Chronic Kidney Disease and Outcomes With Use of Prasugrel Versus Clopidogrel in Patients With Acute Coronary Syndrome Undergoing Percutaneous Coronary Intervention: A Report From the PROMETHEUS Study. JACC Cardiovasc Interv 2017;10:2017-25. [PMID: 28780028 DOI: 10.1016/j.jcin.2017.02.047] [Cited by in Crossref: 25] [Cited by in F6Publishing: 17] [Article Influence: 6.3] [Reference Citation Analysis]
145 Chandrasekhar J, Baber U, Sartori S, Aquino MB, Hájek P, Atzev B, Hudec M, Kiam Ong T, Mates M, Borisov B, Warda HM, den Heijer P, Wojcik J, Iniguez A, Coufal Z, Khashaba A, Munawar M, Gerber RT, Yan BP, Tejedor P, Kala P, Bang Liew H, Lee M, Kalkman DN, Dangas GD, de Winter RJ, Colombo A, Mehran R; MASCOT investigators. 1-Year COMBO stent outcomes stratified by the PARIS bleeding prediction score: From the MASCOT registry.Int J Cardiol Heart Vasc. 2020;31:100605. [PMID: 32953969 DOI: 10.1016/j.ijcha.2020.100605] [Reference Citation Analysis]
146 Baber U. Defining PCI complexity in the contemporary DES era: Clarity or confusion? International Journal of Cardiology 2018;268:94-5. [DOI: 10.1016/j.ijcard.2018.05.044] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
147 Adamski P, Adamska U, Ostrowska M, Navarese EP, Kubica J. Evaluating current and emerging antithrombotic therapy currently available for the treatment of acute coronary syndrome in geriatric populations. Expert Opin Pharmacother 2018;19:1415-25. [PMID: 30132731 DOI: 10.1080/14656566.2018.1510487] [Cited by in Crossref: 5] [Cited by in F6Publishing: 7] [Article Influence: 1.7] [Reference Citation Analysis]
148 Levine GN, Bates ER. It Is Time to End the Dualistic Short Versus Long Duration of Dual Antiplatelet Therapy Debates. Circulation 2017;135:2451-3. [DOI: 10.1161/circulationaha.117.028497] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
149 Hara H, Ono M, Kawashima H, Onuma Y, Serruys PW. Trade-Off Between Bleeding and Thrombotic Risk in Patients With Academic Research Consortium for High Bleeding Risk. JAMA Cardiol 2021. [PMID: 34076662 DOI: 10.1001/jamacardio.2021.1558] [Reference Citation Analysis]
150 Giustino G, Mehran R, Serruys PW, Sabik JF, Milojevic M, Simonton CA, Puskas JD, Kandzari DE, Morice M, Taggart DP, Gershlick AH, Généreux P, Zhang Z, Mcandrew T, Redfors B, Ragosta M, Kron IL, Dressler O, Leon MB, Pocock SJ, Ben-yehuda O, Kappetein AP, Stone GW. Left Main Revascularization With PCI or CABG in Patients With Chronic Kidney Disease. Journal of the American College of Cardiology 2018;72:754-65. [DOI: 10.1016/j.jacc.2018.05.057] [Cited by in Crossref: 31] [Cited by in F6Publishing: 18] [Article Influence: 10.3] [Reference Citation Analysis]
151 Lee OH, Kim BK, Hong SJ, Kim S, Ahn CM, Shin DH, Kim JS, Kang TS, Ko YG, Choi D, Hong MK, Jang Y. Determinants and Clinical Outcomes of Extended Dual Antiplatelet Therapy over 3 Years after Drug-Eluting Stent Implantation: A Retrospective Analysis. Yonsei Med J 2020;61:597-605. [PMID: 32608203 DOI: 10.3349/ymj.2020.61.7.597] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
152 Nathan AS, Sen S, Yeh RW. The risk of bleeding with the use of antiplatelet agents for the treatment of cardiovascular disease. Expert Opin Drug Saf 2017;16:561-72. [PMID: 28387542 DOI: 10.1080/14740338.2017.1315101] [Cited by in Crossref: 11] [Cited by in F6Publishing: 8] [Article Influence: 2.8] [Reference Citation Analysis]
153 Chandrasekhar J, Baber U, Sartori S, Faggioni M, Aquino M, Kini A, Weintraub W, Rao S, Kapadia S, Weiss S, Strauss C, Toma C, Muhlestein B, Defranco A, Effron M, Keller S, Baker B, Pocock S, Henry T, Mehran R. Sex-related differences in outcomes among men and women under 55 years of age with acute coronary syndrome undergoing percutaneous coronary intervention: Results from the PROMETHEUS study: Sex-Related Differences in Young Patients Undergoing PCI. Cathet Cardiovasc Intervent 2017;89:629-37. [DOI: 10.1002/ccd.26606] [Cited by in Crossref: 40] [Cited by in F6Publishing: 35] [Article Influence: 8.0] [Reference Citation Analysis]
154 Kumbhani DJ, Cannon CP, Beavers CJ, Bhatt DL, Cuker A, Gluckman TJ, Marine JE, Mehran R, Messe SR, Patel NS, Peterson BE, Rosenfield K, Spinler SA, Thourani VH. 2020 ACC Expert Consensus Decision Pathway for Anticoagulant and Antiplatelet Therapy in Patients With Atrial Fibrillation or Venous Thromboembolism Undergoing Percutaneous Coronary Intervention or With Atherosclerotic Cardiovascular Disease. Journal of the American College of Cardiology 2021;77:629-58. [DOI: 10.1016/j.jacc.2020.09.011] [Cited by in Crossref: 14] [Cited by in F6Publishing: 10] [Article Influence: 14.0] [Reference Citation Analysis]
155 Ziviello F, Pilgrim T, Kroon H, Ooms JF, van Wiechen MP, El Azzouzi I, Stortecky S, Asami M, Daemen J, de Jaegere PP, Windecker S, van Mieghem NM. HAS-BLED score and actual bleeding in elderly patients undergoing transcatheter aortic valve implantation. Minerva Med 2020;111. [DOI: 10.23736/s0026-4806.19.06154-8] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
156 Faggioni M, Baber U, Sartori S, Chandrasekhar J, Cohen DJ, Henry TD, Claessen BE, Dangas GD, Gibson CM, Krucoff MW, Vogel B, Moliterno DJ, Sorrentino S, Colombo A, Chieffo A, Kini A, Farhan S, Ariti C, Witzenbichler B, Weisz G, Steg PG, Pocock S, Mehran R. Influence of Baseline Anemia on Dual Antiplatelet Therapy Cessation and Risk of Adverse Events After Percutaneous Coronary Intervention: Insights From the PARIS Registry. Circ: Cardiovascular Interventions 2019;12. [DOI: 10.1161/circinterventions.118.007133] [Cited by in Crossref: 6] [Article Influence: 3.0] [Reference Citation Analysis]
157 Park J, Shin J, Kim HL, Song KJ, Jung JH, Lee HJ, You KM, Lim WH, Seo JB, Kim SH, Zo JH, Kim MA; Korean Cardiac Arrest Research Consortium (KoCARC) Investigators. Clinical Factors Associated with Obstructive Coronary Artery Disease in Patients with Out-of-Hospital Cardiac Arrest: Data from the Korean Cardiac Arrest Research Consortium (KoCARC) Registry. J Korean Med Sci 2019;34:e159. [PMID: 31172695 DOI: 10.3346/jkms.2019.34.e159] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
158 Zdanyte M, Wrazidlo RW, Kaltenbach S, Groga-Bada P, Gawaz M, Geisler T, Rath D. Predicting 1-, 3- and 5-year outcomes in patients with coronary artery disease: A comparison of available risk assessment scores. Atherosclerosis 2021;318:1-7. [PMID: 33341519 DOI: 10.1016/j.atherosclerosis.2020.12.007] [Reference Citation Analysis]
159 Peyracchia M, Saglietto A, Biolè C, Raposeiras-roubin S, Abu-assi E, Kinnaird T, Ariza-solé A, Liebetrau C, Manzano-fernández S, Boccuzzi G, Henriques JPS, Wilton SB, Velicki L, Xanthopoulou I, Correia L, Rognoni A, Fabrizio U, Nuñez-gil I, Montabone A, Taha S, Fujii T, Durante A, Gili S, Magnani G, Autelli M, Grosso A, Kawaji T, Blanco PF, Garay A, Quadri G, Queija BC, Huczek Z, Paz RC, González-juanatey JR, Fernández MC, Nie S, D’amico M, Pousa IM, Kawashiri M, Gallo D, Morbiducci U, Dominguez-rodriguez A, Lopez-cuenca A, Cequier A, Alexopoulos D, Iñiguez-romo A, Grossomarra W, Usmiani T, Rinaldi M, D’ascenzo F. Efficacy and Safety of Clopidogrel, Prasugrel and Ticagrelor in ACS Patients Treated with PCI: A Propensity Score Analysis of the RENAMI and BleeMACS Registries. Am J Cardiovasc Drugs 2020;20:259-69. [DOI: 10.1007/s40256-019-00373-1] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
160 Kedhi E, Fabris E, van der Ent M, Buszman P, von Birgelen C, Roolvink V, Zurakowski A, Schotborgh CE, Hoorntje JCA, Eek CH, Cook S, Togni M, Meuwissen M, van Royen N, van Vliet R, Wedel H, Delewi R, Zijlstra F. Six months versus 12 months dual antiplatelet therapy after drug-eluting stent implantation in ST-elevation myocardial infarction (DAPT-STEMI): randomised, multicentre, non-inferiority trial. BMJ 2018;363:k3793. [PMID: 30279197 DOI: 10.1136/bmj.k3793] [Cited by in Crossref: 67] [Cited by in F6Publishing: 46] [Article Influence: 22.3] [Reference Citation Analysis]
161 Lugo LM, Ferreiro JL. Dual antiplatelet therapy after coronary stent implantation: Individualizing the optimal duration. Journal of Cardiology 2018;72:94-104. [DOI: 10.1016/j.jjcc.2018.03.001] [Cited by in Crossref: 8] [Cited by in F6Publishing: 3] [Article Influence: 2.7] [Reference Citation Analysis]
162 Leisman DE. Rare Events in the ICU: An Emerging Challenge in Classification and Prediction. Crit Care Med 2018;46:418-24. [PMID: 29474323 DOI: 10.1097/CCM.0000000000002943] [Cited by in Crossref: 14] [Cited by in F6Publishing: 9] [Article Influence: 7.0] [Reference Citation Analysis]
163 Yamamoto K, Watanabe H, Morimoto T, Domei T, Ohya M, Ogita M, Takagi K, Suzuki H, Nikaido A, Ishii M, Fujii S, Natsuaki M, Yasuda S, Kaneko T, Tamura T, Tamura T, Abe M, Kawai K, Nakao K, Ando K, Tanabe K, Ikari Y, Igarashi Hanaoka K, Morino Y, Kozuma K, Kadota K, Furukawa Y, Nakagawa Y, Kimura T; STOPDAPT-2 Investigators. Very Short Dual Antiplatelet Therapy After Drug-Eluting Stent Implantation in Patients Who Underwent Complex Percutaneous Coronary Intervention: Insight From the STOPDAPT-2 Trial. Circ Cardiovasc Interv 2021;14:e010384. [PMID: 34003662 DOI: 10.1161/CIRCINTERVENTIONS.120.010384] [Cited by in Crossref: 2] [Article Influence: 2.0] [Reference Citation Analysis]
164 Cao D, Mehran R, Dangas G, Baber U, Sartori S, Chandiramani R, Stefanini GG, Angiolillo DJ, Capodanno D, Urban P, Morice M, Krucoff M, Goel R, Roumeliotis A, Sweeny J, Sharma SK, Kini A. Validation of the Academic Research Consortium High Bleeding Risk Definition in Contemporary PCI Patients. Journal of the American College of Cardiology 2020;75:2711-22. [DOI: 10.1016/j.jacc.2020.03.070] [Cited by in Crossref: 47] [Cited by in F6Publishing: 18] [Article Influence: 47.0] [Reference Citation Analysis]
165 Colombo A, Giannini F, Briguori C. Should We Still Have Bare-Metal Stents Available in Our Catheterization Laboratory? J Am Coll Cardiol 2017;70:607-19. [PMID: 28750704 DOI: 10.1016/j.jacc.2017.05.057] [Cited by in Crossref: 22] [Cited by in F6Publishing: 14] [Article Influence: 5.5] [Reference Citation Analysis]
166 Buccheri S, Capodanno D, James S, Angiolillo DJ. Bleeding after antiplatelet therapy for the treatment of acute coronary syndromes: a review of the evidence and evolving paradigms. Expert Opinion on Drug Safety 2019;18:1171-89. [DOI: 10.1080/14740338.2019.1680637] [Cited by in Crossref: 13] [Cited by in F6Publishing: 10] [Article Influence: 6.5] [Reference Citation Analysis]
167 Cao D, Chandiramani R, Chiarito M, Claessen BE, Mehran R. Evolution of antithrombotic therapy in patients undergoing percutaneous coronary intervention: a 40-year journey. Eur Heart J 2021;42:339-51. [PMID: 33367641 DOI: 10.1093/eurheartj/ehaa824] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 7.0] [Reference Citation Analysis]
168 Kanenawa K, Yamaji K, Tashiro H, Morimoto T, Hiromasa T, Hayashi M, Hiramori S, Tomoi Y, Kuramitsu S, Domei T, Hyodo M, Ando K, Kimura T. Frailty and Bleeding After Percutaneous Coronary Intervention. Am J Cardiol 2021;148:22-9. [PMID: 33667444 DOI: 10.1016/j.amjcard.2021.02.041] [Reference Citation Analysis]
169 Yoshida R, Ishii H, Morishima I, Tanaka A, Morita Y, Takagi K, Yoshioka N, Hirayama K, Iwakawa N, Tashiro H, Kojima H, Mitsuda T, Hitora Y, Furusawa K, Tsuboi H, Murohara T. Performance of HAS-BLED, ORBIT, PRECISE-DAPT, and PARIS risk score for predicting long-term bleeding events in patients taking an oral anticoagulant undergoing percutaneous coronary intervention. Journal of Cardiology 2019;73:479-87. [DOI: 10.1016/j.jjcc.2018.10.013] [Cited by in Crossref: 12] [Cited by in F6Publishing: 4] [Article Influence: 6.0] [Reference Citation Analysis]
170 Arps K, Pallazola VA, Cardoso R, Meyer J, Jones R, Latina J, Gluckman TJ, Stone NJ, Blumenthal RS, Mcevoy JW. Clinician's Guide to the Updated ABCs of Cardiovascular Disease Prevention: A Review Part 1. The American Journal of Medicine 2019;132:e569-80. [DOI: 10.1016/j.amjmed.2019.01.016] [Cited by in Crossref: 10] [Cited by in F6Publishing: 6] [Article Influence: 5.0] [Reference Citation Analysis]
171 Valgimigli M, Bueno H, Byrne RA, Collet J, Costa F, Jeppsson A, Jüni P, Kastrati A, Kolh P, Mauri L, Montalescot G, Neumann F, Petricevic M, Roffi M, Steg PG, Windecker S, Zamorano JL, Levine GN, Badimon L, Vranckx P, Agewall S, Andreotti F, Antman E, Barbato E, Bassand J, Bugiardini R, Cikirikcioglu M, Cuisset T, De Bonis M, Delgado V, Fitzsimons D, Gaemperli O, Galiè N, Gilard M, Hamm CW, Ibanez B, Iung B, James S, Knuuti J, Landmesser U, Leclercq C, Lettino M, Lip G, Piepoli MF, Pierard L, Schwerzmann M, Sechtem U, Simpson IA, Uva MS, Stabile E, Storey RF, Tendera M, Van de Werf F, Verheugt F, Aboyans V; ESC Scientific Document Group. 2017 ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS. European Journal of Cardio-Thoracic Surgery 2018;53:34-78. [DOI: 10.1093/ejcts/ezx334] [Cited by in Crossref: 116] [Cited by in F6Publishing: 82] [Article Influence: 29.0] [Reference Citation Analysis]